Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE versus LOPRESSOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE versus LOPRESSOR.
BETAPACE vs LOPRESSOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class III antiarrhythmic agent; prolongs cardiac action potential duration and refractory period by blocking potassium channels, primarily IKr.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors, predominantly in cardiac tissue.
Oral: 80 mg twice daily; may increase up to 160 mg twice daily as needed.
50 mg orally twice daily, titrate up to 100 mg twice daily as needed.
None Documented
None Documented
12 hours (10-20 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment
Terminal elimination half-life: 3-7 hours (mean 4.5 h); may be prolonged in hepatic impairment or elderly
Renal: >90% unchanged drug (sotalol) in urine; biliary/fecal: <10%
Renal: ~95% (primarily as metabolites, <5% unchanged); fecal: ~5%
Category C
Category C
Beta-Blocker
Beta-Blocker